Clinical Trial Update: BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx [Phase 1]

View source ↗

Summary

Phase 1 trial updating BYL719 (alpelisib) plus T-DM1 in HER2-positive metastatic breast cancer patients who progressed on trastuzumab and taxane therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BYL719 (alpelisib)
• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: Northwestern University | Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-03-04